We develop best-in-class microRNA therapeutics for oncology and beyond

Company

InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading miRNA discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging with multiple signal transduction targets simultaneously. With this approach, we address the high unmet medical need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.

Mission statement

InteRNA aspires to improve therapy effectiveness through innovative, intelligent miRNA-based therapeutics for the benefit of patients suffering from cancer and beyond.

Leadership

Management

Supervisory Board

Pieter Rhemrev (observer)

Scientific Advisory Board

Clinical Advisory Board

Investors

Aglaia Oncology Funds
Oost NL
Aurora Science
Waterman Ventures
Provincie Utrecht

Financial support

Provincie Utrecht
Rijksdienst voor Ondernemend Nederland